Suppression of cell death by the secretory form of N-terminal ERC/mesothelin

International Journal of Molecular Medicine

Volumn 26, Issue 2, 2010, Pages 185-191

  Wang, Tegexibaiyin ^a   Kajino, Kazunori ^a   Abe, Masaaki ^a   Tan, Ke ^a   Maruo, Masumi ^a   Sun, Guodong ^a   Hagiwara, Yoshiaki ^b   Maeda, Masahiro ^b   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Cell death; ERC mesothelin; MAP kinase; Secretory form

Indexed keywords

BROXURIDINE; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; CULTURE MEDIUM; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; CELL SURVIVAL; CULTURE MEDIUM; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOLECULAR CLONING; SECRETION (PROCESS); TUMOR CELL LINE;

ANALYSIS OF VARIANCE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLONING, MOLECULAR; CULTURE MEDIA, CONDITIONED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GPI-LINKED PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, FLUORESCENCE;

EID: 77955738538     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000451     Document Type: Article

References (23)

1. Hino O, Kobayashi E, Nishizawa M, Kubo Y, Kobayashi T, Hirayama Y, Takai S, Kikuchi Y, Tsuchiya H, Orimoto K, Kajino K and Takahara T: Renal carcinogenenesis in the Eker rat. J Cancer Res Clin Oncol 121: 602-605,1995.
2. Yamashita Y, Yokoyama M, Kobayashi E, Takai S and Hino O: Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 275: 134-140, 2000. (Pubitemid 30663642)
3. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996. (Pubitemid 26041483)
4. Chang K, Pastan I and Willingham MC: Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 51: 548-554, 1992.
5. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H and Hampton GM: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34: 605-609, 2003.
6. Cao D, Ji H and Ronnett BM: Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 24: 67-72, 2005.
7. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ and Morin PJ: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60: 6281-6287, 2000.
8. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE and Hruban RH: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868, 2001.
9. Kojima T, Oh-Eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N and Yamaguchi N: Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 270: 21984-21990, 1995.
10. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y and Hino O: Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97: 928-932, 2006.
11. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH and Pastan I: Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12: 4225-4231, 2006.
12. Nakaishi M, Kajino K, Ikesue M, Hagiwara Y, Kuwahara M, Mitani H, Horikoshi-Sakuraba Y, Segawa T, Kon S, Maeda M, Wang T, Abe M, Yokoyama M and Hino O: Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin. Cancer Sci 98: 659-664, 2007.
13. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M and Miyajima A: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198, 2004. (Pubitemid 38295982)
14. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I and Patankar MS: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitate peritoneal metastasis of ovarian tumors. Mol Cancer 5: 50, 2006.
15. Bharadwaj U, Li M, Chen C and Yao Q: Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 6: 1755-1765, 2008.
16. Uehara N, Matsuoka Y and Tsubura A: Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 6: 186-193, 2008.
17. Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH and Cheng WF: Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J 424: 449-458, 2009.
18. Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M and Hino O: Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int 59: 161-166, 2009.
19. Fukazawa H, Noguchi K, Masumi A, Murakami Y and Uehara Y: BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors. Mol Cancer Ther 3: 1281-1288, 2004. (Pubitemid 39445336)
20. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK and Brugge JS: Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5: 733-740, 2003.
21. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, Lomas M, Arndt GM, Tang Y, Nakada M, Yan L and Hait WN: Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem 281: 9719-9727, 2006.
22. Hassan R, Bera T and Pastan I: Mesothelin: A new target for immunotherapy. Clin Cancer Res 10: 3937-3942, 2004.
23. Hassan R and Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53, 2008.